IP Library Granted Patent US 7,458,378
Granted Patent B2
US 7,458,378 · App. 10/912,329 · Granted Dec 2, 2008

Systems methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,458,378
App. No.
10/912,329
Granted
Dec 2, 2008
Kind
B2
Abstract

Systems and methods apply a selected treatment agent or agents into contact with tissue at or in the region of a dysfunctional sphincter (in the case of GERD, fecal incontinence, or other dysfunctional sphincter disorders) to affect improved sphincter barrier function and/or to disrupt abnormal nerve pathways. The treatment agent can include at least one cytokine and/or at least one tissue bulking agent and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or applied as a supplementary treatment before, during or after a primary intervention.

Claims (14)

1. A method of treating fecal incontinence comprising

selecting at least one vanilloid compound,

providing a source of the at least one vanilloid compound,

selecting a targeted tissue region at or near an anal sphincter,

deploying a catheter carrying on its distal end a tissue piercing element adjacent the targeted tissue region,

coupling the catheter to the source of the at least one vanilloid compound,

manipulating the tissue piercing element to enter subsurface tissue in the targeted tissue region,

injecting through the tissue piercing element the at least one vanilloid compound into the subsurface tissue.

2. A method as in claim 1

wherein injection of the at least one vanilloid compound limits a fecal sampling reflex.

3. A method as in claim 1

wherein injection of the at least one vanilloid compound modulates an abnormal nerve feedback pathway in the rectum.

4. A method as in claim 1 , further comprising

applying radiofrequency energy through the tissue piercing element to incite a wound in the subsurface tissue into which the at least one vanilloid compound is injected.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2018
From: HORIZON CREDIT II LLC
To: MEDERI RF, LLC
Reel/Frame 046069/0567 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2018
From: MEDERI THERAPEUTICS INC.
To: HORIZON CREDIT II LLC
Reel/Frame 046076/0317 →
SECURITY INTEREST Recorded Aug 3, 2015
From: MEDERI THERAPEUTICS INC.
To: HORIZON CREDIT II LLC
Reel/Frame 036252/0728 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2009
From: RESPIRATORY DIAGNOSTIC, INC.
To: MEDERI THERAPEUTICS, INC.
Reel/Frame 022597/0080 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2008
From: CURON MEDICAL, INC. BY JOHN T. KENDALL, TRUSTEE
To: RESPIRATORY DIAGNOSTICS, INC.
Reel/Frame 021118/0025 →